

Citation: Li Jun, Huang Danfeng, Zhang Huaiyuan, Zhang Xinghu, Wang Juanjuan, Wang Ke-Hu, Su Yingpeng, Hu Yulai. Indium-Promoted Preparation of α-Methylene-γ-trifluoromethyl-γ-lactams via One-Pot Reaction[J]. Chinese Journal of Organic Chemistry, 2017, 37(11): 2985-2992. doi: 10.6023/cjoc201703050

铟粉促进下“一锅法”合成α-亚甲基-γ-三氟甲基-γ-丁内酰胺化合物
-
关键词:
- 一锅法
- / 铟粉
- / 三氟乙醛甲基半缩醛
- / 三氟苯乙酮
- / 2-(溴甲基)丙烯酸乙酯
- / 酰肼
- / α-亚甲基-γ-三氟甲基-γ-丁内酰胺
English
Indium-Promoted Preparation of α-Methylene-γ-trifluoromethyl-γ-lactams via One-Pot Reaction
-
α-亚甲基-γ-丁内酰胺及其衍生物广泛存在于具有生物活性的天然产物及药物的结构之中[1~3].它和α-亚甲基-γ-丁内酯在抗菌、抗炎和抗过敏方面具有相似的性质[2], 但是其毒副作用比后者小, 更适用于抗癌、抗肿瘤以及消炎药物的合成与临床应用.因此, 如何获得α-亚甲基-γ-丁内酰胺化合物备受化学家和药物学家的青睐.目前, 除了从天然产物分离得到这类物质外, 人们已发展了各种合成α-亚甲基-γ-丁内酰胺的方法[3], 如分子内的Baylis-Hillman反应[1a, 4]、Baylis-Hillman醇及其衍生物作为前体参与的反应[2a, 5]、Wittig或Horner-Wadsworth-Emmons反应[6]、过渡金属试剂对亚胺的加成[7]以及自由基反应[8]等.其中, 烯丙基有机金属试剂对亚胺的加成是合成α-亚甲基-γ-丁内酰胺的一种颇具吸引力的方法.例如, 金属锌[5e, 9]、铟[10]和锡[11]促进的烯丙基化反应和有机硼试剂[12]与亚胺的反应都已成功得到了α-亚甲基-γ-丁内酰胺化合物.
另外, 向有机物分子中引入强吸电子的三氟甲基团可以极大地改变有机化合物的理化性质及生理活性[13].例如, 含三氟甲基的药物分子往往具有好的亲油性和抗新陈代谢氧化的稳定性, 增强了其生物利用度, 因此在药物或潜在的药物分子中引入三氟甲基基团具有重要意义.通常, 向有机分子中引入三氟甲基的方法主要有两种:三氟甲基试剂法和三氟甲基合成砌块法[13~15].本小组[16]致力于使用价廉易得的三氟甲基试剂或三氟甲基砌块作为氟源, 构建了一系列三氟甲基化合物.在我们[17]探索铟粉促进下“一锅法”合成三氟甲基高烯丙基酰肼化合物的工作基础上, 在铟粉促进下, 以三氟乙醛甲基半缩醛或三氟苯乙酮为三氟甲基合成砌块, 通过它与酰肼、2-(溴甲基)丙烯酸乙酯的“一锅法”环化反应, 提供了一种制备含三氟甲基的α-亚甲基-γ-丁内酰胺化合物的新方法, 特别是通过该反应构筑了一个含三氟甲基的叔碳中心, 为进一步探索催化不对称合成α-亚甲基-γ-三氟甲基-γ-丁内酰胺化合物奠定了基础.
1 结果与讨论
1.1 铟粉促进下以三氟乙醛甲基半缩醛为三氟甲基合成砌块的“一锅法”反应
在铟粉促进下, 由三氟乙醛甲基半缩醛、苯甲酰肼和烯丙基溴的“一锅法”反应[17]制备三氟甲基高烯丙基酰肼化合物的工作基础上, 我们用2-(溴甲基)丙烯酸乙酯代替烯丙基溴, 尝试了铟粉促进下三氟乙醛甲基半缩醛1、苯甲酰肼(2a)和2-(溴甲基)丙烯酸乙酯(3)的“一锅法”反应.结果发现, 在四氢呋喃溶剂中回流条件下, 得到了预期产物4a, 产率为68%.当反应在乙醇[18]溶剂中进行时, 4a的产率可达81%(表 1, Entry 1).然后, 在此条件下, 我们探索了其他酰肼对该反应的适用性(Eq. 1), 结果见表 1.
Entry R1 Product Isolated yield/% 1 C6H5 4a 81 2 o-MeC6H4 4b Trace 3 m-MeC6H4 4c 51 4 p-MeC6H4 4d 84 5 p-MeOC6H4 4e 89 6 p-FC6H4 4f 71 7 p-ClC6H4 4g 73 8 p-CF3C6H4 4h 86 9 m-BrC6H4 4i 75 10 2-Furyl 4j 81 11 2-Naphthyl 4k 72 12 Me — 0 13 n-C17H35 — 0 aA mixture of 1 (0.3 mmol), acylhydrazine (0.2 mmol) in EtOH (4.0 mL) was stirred at reflux for 3 h, then 3 (0.5 mmol) and in powder (0.3 mmol) were added and stirred at reflux for another 21 h. 由表 1可知, 无论芳香酰肼还是杂环酰肼, 都能与三氟乙醛甲基半缩醛、2-(溴甲基)丙烯酸乙酯和铟粉发生“一锅法”反应, 得到相应的α-亚甲基-γ-三氟甲基-γ-丁内酰胺化合物.对于芳香酰肼, 苯环上的取代基的电子性质对反应影响不大, 不管取代基是吸电子的还是供电子的, 所得产物的产率都在71%以上(Entries 1~9).然而, 取代基在苯环上的位置对反应有较大影响.例如, p-甲基苯甲酰肼作为底物反应时4d产率为84%, m-甲基苯甲酰肼反应时4c产率降为51%, 而o-甲基苯甲酰肼反应时仅有痕量的4b产生(Entries 2~4).对于2-呋喃酰肼和2-萘酰肼参与的反应, 也能以高产率得到目标产物(Entries 10, 11).对于链状的脂肪族酰肼, 不管碳链是长链还是短链, 反应都没有发生(Entries 12, 13).这可能是由于脂肪族酰肼形成的酰腙不如芳香酰肼形成的酰腙稳定, 因此不利于下一步烯丙基化/环化反应的进行.
1.2 铟粉促进下以三氟苯乙酮为三氟甲基合成砌块的“一锅法”反应
在铟粉促进下, 三氟苯乙酮、苯甲酰肼和烯丙基溴“一锅法”反应[17]的基础上, 我们使用2-(溴甲基)丙烯酸乙酯代替烯丙基溴进行上述反应(Eq. 2).结果发现, 该“一锅法”反应在乙醇溶剂中, 对甲苯磺酸(PTSA)催化下能够顺利进行, 并且以47%的产率得到环化产物6a(表 2, Entry 1);在PTSA和Ni(ClO)4·6H2O的双催化[17]下, 环化产物6a的产率仅为52%(表 2, Entry 2), 没有明显提高.然后我们对反应的物料比重新进行了筛选(表 2, Entries 3~6).最终发现在PTSA作为催化剂, 三氟苯乙酮(5a)、苯甲酰肼(2a)、2-(溴甲基)丙烯酸乙酯(3)和铟粉的物质的量之比为1: 1.2: 3.5: 2.5时, 6a的产率达到了80%.
Entry Molar ratio of 5a/2a/3/In Catalyst/mol% Isolated yield/% 1 1/1.2/2.5/1.5 PTSA (20) 47 2 1/1.2/2.5/1.5 PTSA (20) Ni(ClO)4·6H2O (10) 52 3 1/1.2/3/1.5 PTSA (20) 54 4 1/1.2/3/2 PTSA (20) 56 5 1/1.2/3.5/2 PTSA (20) 72 6 1/1.2/3.5/2.5 PTSA (20) 80 a A mixture of 5a (0.2 mmol), 2a (0.24 mmol), catalyst (20 mol%, 0.04 mmol) in EtOH (3.0 mL) was stirred at reflux for 5 h, then 3(0.5~0.7 mmol). In powder (0.3~0.5 mmol) were added and stirred at reflux for another 19 h. 在上述最优的反应条件下, 我们探索了不同的三氟甲基酮和不同的酰肼与2-(溴甲基)丙烯酸乙酯和铟粉的“一锅法”反应(Eq. 3).由表 3可知, 对于芳香酰肼和三氟苯乙酮, 不管苯环上连有供电子基还是吸电子基, 反应都能顺利进行并且以较好的产率得到相应环化产物(Entries 1~6, 8~14).但是, 对于苯环上连有强吸电子基CF3的酰肼和三氟苯乙酮, 反应不能发生(Entries 7, 15).研究结果还发现, 取代基在苯环上的位置对反应有较大影响.例如, p-甲基苯甲酰肼反应时6c产率为82%, m-甲基苯甲酰肼反应时6d产率降为74%, o-甲基苯甲酰肼反应时6e产率仅为51% (Entries 3~5).对于氯代三氟苯乙酮, 当氯原子分别在苯环上的对位和间位时反应所得产物6j和6k的产率分别是78%和70%, 而o-氯代三氟苯乙酮的反应却不能发生(Entries 11~13).对于杂环酰肼, 如2-呋喃酰肼的反应产率也能达到80% (Entry 8).然而, 对于脂肪酰肼, 如乙酰肼, 反应却没有发生(Entry 16).这仍然是由于脂肪族酰肼的生成的酰腙不稳定, 导致烯丙基化/环化反应不能发生.
Entry R1 R2 Product Isolated yield/% 1 Ph Ph 6a 80 2 p-MeOC6H4 Ph 6b 83 3 p-MeC6H4 Ph 6c 82 4 m-MeC6H4 Ph 6d 74 5 o-MeC6H4 Ph 6e 51 6 p-ClC6H4 Ph 6f 78 7 p-CF3C6H4 Ph — 0 8 2-Furyl Ph 6g 80 9 Ph p-MeOC6H4 6h 86 10 Ph p-MeC6H4 6i 82 11 Ph p-ClC6H4 6j 78 12 Ph m-ClC6H4 6k 70 13 Ph o-ClC6H4 — Trace 14 Ph m-BrC6H4 6l 72 15 Ph p-CF3C6H4 — 0 16 Me Ph — 0 a A mixture of 5 (0.2 mmol), 2(0.24 mmol), PTSA (20 mol%, 0.04 mmol) in EtOH (3.0 mL) was stirred at reflux for 5 h, then 3(0.7 mmol). In powder (0.5 mmol) were added and stirred at reflux for another 19 h. 1.3 反应机理探讨
在文献[19]报道和实验结果基础上, 我们认为铟粉促进下“一锅法”合成α-亚甲基-γ-三氟甲基-γ-丁内酰胺的反应机理可能如Scheme 1所示.以三氟乙醛甲基半缩醛为例说明:首先, 三氟乙醛甲基半缩醛1和酰肼2反应形成酰腙7; 然后, 7与金属铟和2-(溴甲基)丙烯酸乙酯(3)形成的烯丙基铟试剂8[19b]发生亲核加成反应, 得到中间体9; 最后, 9发生环化和水解反应生成4.
2 结论
综上所述, 本文报道了铟粉促进下, 通过三氟乙醛甲基半缩醛或三氟苯乙酮与酰肼和2-(溴甲基)丙烯酸乙酯的“一锅法”反应, 合成α-亚甲基-γ-三氟甲基-γ-丁内酰胺化合物的方法.该方法使用价廉易得的三氟乙醛甲基半缩醛或三氟苯乙酮作为三氟甲基合成砌块, 具有反应条件温和、产率高、操作简单等优点.特别是, 当三氟苯乙酮作为氟源时, 通过该反应生成的α-亚甲基-γ-丁内酰胺化合物具有一个含三氟甲基的叔碳中心, 为进一步合成该类具有重要药理活性的化合物提供了一种有效的方法.
3 实验部分
3.1 仪器与试剂
核磁共振谱用BRUKER PT jxf790425AM 400 MHz或Agilent DD2 600 MHz型核磁共振仪测定, 以氘代氯仿作为溶剂, TMS为内标; 高分辨质谱用Bruker APEX Ⅱ傅里叶变换离子回旋共振质谱仪测定, ESI源; 熔点测定用显微熔点测定仪测定, 温度未校正.化合物2b~2m按照文献[20]方法自制, 其它试剂均为国产分析纯级.
3.2 实验方法
3.2.1 化合物4a的合成
在50 mL的圆底烧瓶中, 依次加入三氟乙醛甲基半缩醛(1) (0.039 g, 0.30 mmol)、苯甲酰肼(2a) (0.027 g, 0.20 mmol)和4 mL乙醇, 将此混合液在回流条件下搅拌.薄层色谱(TLC)检测反应, 3 h后有酰腙大量生成.此时加入2-(溴甲基)丙烯酸乙酯(3) (0.096 g, 0.50 mmol)和铟粉(0.034 g, 0.30 mmol), 继续回流此反应混合物, TLC检测21 h反应完全.然后向反应混合物中加入3 mL饱和氯化铵溶液, 搅拌10 min, 用乙酸乙酯(5 mL×3)萃取, 分出有机相, 用无水硫酸镁干燥, 蒸去溶剂后, 进行柱层析[V(石油醚): V(乙酸乙酯)=5: 1]分离得产物4a (44 mg).化合物4b~4k制备方法同4a.
N-苯甲酰胺基-α-亚甲基-γ-三氟甲基-γ-丁内酰胺(4a):白色固体; 46.0 mg, 产率81%. m.p. 177~178 ℃; 1H NMR (600 MHz, CDCl3) δ: 10.01 (br, 1H, NH), 7.78 (d, J=8.4 Hz, 2H, ArH), 7.42 (s, 1H, ArH), 7.29 (t, J=7.8 Hz, 2H, ArH), 6.23 (s, 1H, =CH2), 5.59 (s, 1H, =CH2), 4.50~4.48 (m, 1H, CF3CH), 3.25~3.20 (m, 1H, CH2), 2.89 (d, J=18.0 Hz, 1H, CH2); 13C NMR (150 MHz, CDCl3) δ: 168.0, 165.5, 132.9, 132.4, 130.5, 128.5, 127.5, 124.6 (q, JC-F=280.1 Hz), 120.6, 56.7 (q, JC-F=31.8 Hz), 24.8; 19F NMR (376 MHz, CDCl3) δ: -76.9 (d, JF-H=6.4 Hz); HRMS (ESI) calcd for C13H12F3N2O2[M+H]+ 285.0845, found 285.0842.
N-(3-甲基苯甲酰胺基)-α-亚甲基-γ-三氟甲基-γ-丁内酰胺(4c):白色固体; 30.1 mg, 产率51%. m.p. 141~143 ℃; 1H NMR (600 MHz, CDCl3) δ: 9.80 (s, 1H, NH), 7.61 (d, J=6.0 Hz, 2H, ArH), 7.23 (d, J=7.8 Hz, 1H, ArH), 7.18 (t, J=7.8 Hz, 1H, ArH), 6.22 (t, J=2.4 Hz, 1H, =CH2), 5.58 (t, J=2.4 Hz, 1H, =CH2), 4.52~4.48 (m, 1H, CF3CH), 3.25~3.20 (m, 1H, CH2), 2.91~2.87 (m, 1H, CH2), 2.27 (s, 3H, CH3); 13C NMR (150 MHz, CDCl3) δ: 167.9, 165.6, 138.3, 133.1, 133.0, 130.5, 128.4, 128.1, 124.6 (q, JC-F=280.1 Hz), 124.5, 120.4, 56.7 (q, JC-F=31.7 Hz), 24.8, 21.1;19F NMR (376 MHz, CDCl3) δ: -76.9 (d, JF-H=6.4 Hz); HRMS (ESI) calcd for C14H13F3N2O2Na[M+Na]+ 321.0821, found 321.0826.
N-(4-甲基苯甲酰胺基)-α-亚甲基-γ-三氟甲基-γ-丁内酰胺(4d):白色固体; 50.1 mg, 产率84%. m.p. 140~142 ℃; 1H NMR (600 MHz, CDCl3) δ: 9.92 (s, 1H, NH), 7.67 (d, J=7.8 Hz, 2H, ArH), 7.06 (d, J=7.8 Hz, 2H, ArH), 6.20 (s, 1H, =CH2), 5.56 (s, 1H, =CH2, ), 4.47 (s, 1H, CF3CH), 3.22~3.18 (m, 1H, CH2), 2.87 (d, J=17.4 Hz, 1H, CH2), 2.31 (s, 3H, CH3); 13C NMR (150 MHz, CDCl3) δ: 168.0, 165.5, 143.0, 133.0, 129.1, 127.8, 127.5, 124.6 (q, JC-F=280.1 Hz), 120.4, 56.8 (q, JC-F=31.7 Hz), 24.8, 21.4;19F NMR (376 MHz, CDCl3) δ: -76.9 (d, JF-H=6.0 Hz); HRMS (ESI) calcd for C14H13F3N2O2Na[M+Na]+ 321.0821, found 321.0828.
N-(4-甲氧基苯甲酰胺基)-α-亚甲基-γ-三氟甲基-γ-丁内酰胺(4e):白色固体; 55.9 mg, 产率89%. m.p. 158~160 ℃; 1H NMR (600 MHz, CDCl3) δ: 9.94 (br, 1H, NH), 7.77 (d, J=8.4 Hz, 2H, ArH), 6.76~6.75 (m, 2H, ArH), 6.22 (s, 1H, =CH2), 5.58 (s, 1H, =CH2), 4.47 (s, 1H, CF3CH), 3.79 (s, 3H, OCH3), 3.24~3.20 (m, 1H, CH2), 2.88 (d, J=17.4 Hz, 1H, CH2); 13C NMR (150 MHz, CDCl3) δ: 168.1, 165.1, 162.9, 133.0, 129.5, 124.6 (q, JC-F=279.9 Hz), 122.9, 120.4, 113.7, 56.9 (q, JC-F=31.7 Hz), 55.3, 24.8; 19F NMR (376 MHz, CDCl3) δ: -76.9 (d, JF-H=6.4 Hz); HRMS (ESI) calcd for C14H13F3N2O3Na[M+Na]+ 337.0770, found 337.0778.
N-(4-氟苯甲酰胺基)-α-亚甲基-γ-三氟甲基-γ-丁内酰胺(4f):白色固体; 42.9 mg, 产率71%. m.p. 154~156 ℃; 1H NMR (600 MHz, CDCl3) δ: 10.19 (s, 1H, NH), 7.82~7.79 (m, 2H, ArH), 6.96 (t, J=8.4 Hz, 2H, ArH), 6.24 (s, 1H, =CH2), 5.61 (s, 1H, =CH2), 4.46 (CF3CH, s, 1H), 3.25~3.21 (m, 1H, CH2), 2.90 (d, J=18.0 Hz, 1H, CH2); 13C NMR (150 MHz, CDCl3) δ: 168.3, 165.2 (d, J=252.5 Hz), 164.2, 132.8, 130.0 (d, J=9.2 Hz), 126.6 (d, J=2.8 Hz), 124.5 (q, JC-F=280.1 Hz), 120.8, 115.6 (d, J=22.0 Hz), 56.8 (q, JC-F=32.0 Hz), 24.8; 19F NMR (376 MHz, CDCl3) δ: -77.0 (d, JF-H=6.4 Hz), 106.5; HRMS (ESI) calcd for C13H10F4N2O2Na[M+Na]+ 325.0571, found 325.0577.
N-(4-氯苯甲酰胺基)-α-亚甲基-γ-三氟甲基-γ-丁内酰胺(4g):白色固体; 46.4 mg, 产率73%. m.p. 160~162 ℃; 1H NMR (600 MHz, CDCl3) δ: 10.25 (s, 1H, NH), 7.68 (d, J=8.4 Hz, 2H, ArH), 7.23 (d, J=8.4 Hz, 2H, ArH), 6.22 (s, 1H, =CH2), 5.60 (s, 1H, =CH2), 4.45~4.42 (m, 1H, CF3CH), 3.23~3.19 (m, 1H, CH2), 2.90~2.86 (m, 1H, CH2); 13C NMR (150 MHz, CDCl3) δ: 168.3, 164.3, 138.9, 132.7, 128.8, 128.7, 128.6, 124.4 (q, JC-F=280.1 Hz), 120.9, 56.8 (q, JC-F=31.8 Hz), 24.8; 19F NMR (376 MHz, CDCl3) δ: -77.0 (d, JF-H=6.4 Hz); HRMS (ESI) calcd for C13H14ClF3N3O2[M+NH4]+ 336.0721, found 336.0723.
N-(4-三氟甲基苯甲酰胺基)-α-亚甲基-γ-三氟甲基-γ-丁内酰胺(4h):白色固体; 60.5 mg, 产率86%. m.p. 137~138 ℃; 1H NMR (600 MHz, CDCl3) δ: 10.16 (s, 1H, NH), 7.84 (d, J=8.4 Hz, 2H, ArH), 7.53 (d, J=8.4 Hz, 2H, ArH), 6.27 (t, J=2.4 Hz, 1H, =CH2), 5.64 (s, 1H, =CH2), 4.49~4.46 (m, 1H, CF3CH), 3.28~3.23 (m, 1H, CH2), 2.93 (dd, J=17.4, 2.4 Hz, 1H, CH2); 13C NMR (150 MHz, CDCl3) δ: 168.1, 163.9, 134.0 (q, JC-F=32.4 Hz), 133.5, 132.5, 127.8, 125.6 (q, J=3.6 Hz), 124.4 (q, JC-F=280.0 Hz), 123.4 (q, JC-F=270.7 Hz), 121.1, 56.9 (q, JC-F=32.0 Hz), 24.9; 19F NMR (376 MHz, CDCl3) δ: -67.8, -81.0 (d, JF-H=6.0 Hz); HRMS (ESI) calcd for C14H10F6N2O2Na[M+Na]+ 375.0539, found 375.0544.
N-(3-溴苯甲酰胺基)-α-亚甲基-γ-三氟甲基-γ-丁内酰胺(4i):白色固体; 54.3 mg, 产率75%. m.p. 122~124 ℃; 1H NMR (600 MHz, CDCl3) δ: 10.03 (s, 1H, NH), 7.89 (s, 1H, ArH), 7.71 (d, J=7.8 Hz, 1H, ArH), 7.58 (d, J=7.8 Hz, 1H, ArH), 7.19~7.16 (m, 1H, ArH), 6.23 (t, J=2.4 Hz, 1H, =CH2), 5.60 (s, 1H, =CH2), 4.47~4.44 (m, 1H, CF3CH), 3.25~3.20 (m, 1H, CH2), 2.90 (dd, J=17.4, 2.4 Hz, 1H, CH2); 13C NMR (150 MHz, CDCl3) δ: 168.0, 163.9, 135.5, 132.7, 132.2, 130.9, 130.1, 125.6, 124.4 (q, JC—F=280.2 Hz), 122.8, 120.9, 56.8 (q, JC—F=31.6 Hz), 24.8;19F NMR (376 MHz, CDCl3) δ: -76.9 (d, JF-H=6.0 Hz); HRMS (ESI) calcd for C13H10BrF3N2O2Na[M+Na]+ 384.9770, found 384.9777.
N-(2-呋喃甲酰胺基)-α-亚甲基-γ-三氟甲基-γ-丁内酰胺(4j):白色固体; 44.4 mg, 产率81%. m.p. 154~155 ℃; 1H NMR (400 MHz, CDCl3) δ: 9.59 (br, 1H, NH), 7.42 (d, J=1.6 Hz, 1H, C4H3O), 7.14 (d, J=3.2 Hz, 1H, C4H3O), 6.42 (dd, J=4.0, 2.0 Hz, 1H, C4H3O), 6.23 (t, J=2.4 Hz, 1H, =CH2), 5.59 (t, J=2.4 Hz, 1H, =CH2), 4.50~4.44 (m, 1H, CF3CH), 3.23 (dd, J=17.6, 9.2 Hz, 1H, CH2), 2.93~2.88 (m, 1H, CH2); 13C NMR (150 MHz, CDCl3) δ: 167.3, 156.5, 145.4, 145.2, 132.8, 124.6 (q, JC—F=280.1 Hz), 120.5, 116.4, 112.0, 56.9 (q, JC—F=31.8 Hz), 24.8 (d, J=1.8 Hz); 19F NMR (376 MHz, CDCl3) δ: -76.9 (d, JF-H=6.4 Hz); HRMS (ESI) calcd for C11H9F3N2O3Na[M+Na]+ 297.0457, found 297.0461.
N-(2-萘甲酰胺基)-α-亚甲基-γ-三氟甲基-γ-丁内酰胺(4k):白色固体; 48.1 mg, 产率72%. m.p. 187~189 ℃; 1H NMR (600 MHz, CDCl3) δ: 8.60 (s, 1H, NH), 8.35 (d, J=7.8 Hz, 1H, ArH), 7.90 (d, J=8.4 Hz, 1H, ArH), 7.83 (d, J=7.8 Hz, 1H, ArH), 7.68 (d, J=6.6 Hz, 1H, ArH), 7.55~7.50 (m, 2H, ArH), 7.36~7.34 (m, 1H, ArH), 6.18 (d, J=1.8 Hz, 1H, =CH2), 5.55 (d, J=1.2 Hz, 1H, =CH2), 4.59 (s, 1H, CF3CH), 3.21 (CH2, dd, J=16.2, 9.6 Hz, 1H), 2.88 (CH2, d, J=17.4 Hz, 1H); 13C NMR (150 MHz, CDCl3) δ: 167.8, 167.2, 133.5, 132.7, 131.9, 130.2, 129.9, 128.3, 127.6, 126.6, 126.1, 125.1, 124.7 (q, JC-F=279.6 Hz), 124.5, 120.6, 56.7 (q, JC-F=31.6 Hz), 24.7; 19F NMR (376 MHz, CDCl3) δ: -76.7 (d, JF-H=6.0 Hz); HRMS (ESI) calcd for C17H13F3N2O2Na[M+Na]+ 357.0821, found 357.0826.
3.2.2 化合物6a的合成
在50 mL的圆底烧瓶中, 依次加入三氟苯乙酮(5a) (0.034 g, 0.20 mmol)、苯甲酰肼(2a) (0.033 g, 0.24 mmol)、对甲苯磺酸(0.007 g, 0.04 mmol)和EtOH (3 mL), 将混合物在回流条件下搅拌. TLC检测反应, 5 h后有酰腙大量的生成.此时加入2-(溴甲基)丙烯酸乙酯(3) (0.135 g, 0.70 mmol)、铟粉(0.057 g, 0.50 mmol), 继续搅拌回流此反应混合物, TLC检测19 h后反应完全.然后向反应混合物中加入3 mL饱和氯化铵溶液, 搅拌10 min, 用乙酸乙酯(5 mL×3)萃取, 分出有机相, 用无水硫酸镁干燥, 蒸去溶剂后, 进行柱层析[V(石油醚): V(乙酸乙酯)=5: 1]分离得产物6a (58 mg).化合物6b~6l制备方法同6a.
N-苯甲酰胺基-α-亚甲基-γ-苯基-γ-三氟甲基-γ-丁内酰胺(6a):白色固体; 57.6 mg, 产率80%. m.p. 66~67 ℃; 1H NMR (600 MHz, CDCl3) δ: 8.60 (NH, br, 1H), 7.61 (d, J=7.2 Hz, 2H, ArH), 7.54 (d, J=7.8 Hz, 1H, ArH), 7.39~7.30 (m, 4H, ArH), 7.25~7.22 (m, 2H), 6.28 (s, 1H, =CH2), 5.59 (s, 1H, =CH2), 3.46 (d, J=18.0 Hz, 1H, CH2), 3.22 (d, J=18.0 Hz, 1H, CH2); 13C NMR (100 MHz, CDCl3) δ: 166.4, 165.5, 133.9, 133.0, 132.0, 130.9, 129.1, 128.6, 128.3, 127.5, 127.1, 125.7 (q, JC-F=286.3 Hz), 119.8, 68.8 (q, JC-F=27.5 Hz), 37.0; 19F NMR (376 MHz, CDCl3) δ: -72.4. HRMS (ESI) calcd for C19H16F3N2O2[M+H]+ 361.1158, found 361.1155.
N-(4-甲氧基苯甲酰胺基)-α-亚甲基-γ-苯基-γ-三氟甲基-γ-丁内酰胺(6b):白色固体; 64.7 mg, 产率83%. m.p. 128~130 ℃; 1H NMR (600 MHz, CDCl3)δ: 8.90 (br, 1H, NH), 7.53 (d, J=7.8 Hz, 4H, ArH), 7.35 (t, J=7.2 Hz, 1H, ArH), 7.20 (t, J=7.2 Hz, 2H, ArH), 6.83 (d, J=8.4 Hz, 2H, ArH), 6.25 (s, 1H, =CH2), 5.57 (s, 1H, =CH2), 3.72 (s, 3H, OCH3), 3.42 (d, J=18.0 Hz, 1H, CH2), 3.21 (d, J=17.4 Hz, 1H, CH2); 13C NMR (150 MHz, CDCl3) δ: 166.4, 165.4, 159.7, 133.3, 131.9, 130.9, 128.7, 128.2, 127.5, 125.8 (q, JC-F=286.5 Hz), 125.4, 119.5, 113.8, 68.5 (q, JC-F=27.0 Hz), 55.1, 36.9; 19F NMR (376 MHz, CDCl3) δ: -72.9; HRMS (ESI) calcd for C20H18F3N2O3[M+H]+ 391.1264, found 391.1261.
N-(4-甲基苯甲酰胺基)-α-亚甲基-γ-苯基-γ-三氟甲基-γ-丁内酰胺(6c):白色固体; 61.4 mg, 产率82%. m.p. 102~104 ℃; 1H NMR (600 MHz, CDCl3) δ: 8.57 (br, 1H, NH), 7.62 (d, J=7.2 Hz, 2H, ArH), 7.44 (d, J=8.4 Hz, 2H, ArH), 7.35~7.29 (m, 3H, ArH), 7.02 (d, J=8.4 Hz, 2H, ArH), 6.28 (s, 1H, =CH2), 5.58 (s, 1H, =CH2), 3.46 (d, J=18.0 Hz, 1H, CH2), 3.22 (d, J=18.0 Hz, 1H, CH2), 2.30 (s, 3H, CH3); 13C NMR (150 MHz, CDCl3) δ: 166.4, 165.4, 142.5, 134.1, 133.1, 129.0, 128.8, 128.5, 128.1, 127.5, 127.1, 125.8 (q, JC-F=285.0 Hz), 119.6, 68.8 (q, JC-F=27.0 Hz), 36.9, 21.4; 19F NMR (376 MHz, CDCl3) δ: -72.4; HRMS (ESI) calcd for C20H18F3N2O2[M+H]+ 375.1315, found 375.1310.
N-(3-甲基苯甲酰胺基)-α-亚甲基-γ-苯基-γ-三氟甲基-γ-丁内酰胺(6d):白色固体; 55.5 mg, 产率74%. m.p. 134~136 ℃; 1H NMR (600 MHz, CDCl3) δ: 7.86 (NH, br, 1H), 7.62 (d, J=7.2 Hz, 2H, ArH), 7.43 (s, 1H, ArH), 7.38~7.33 (m, ArH, 4H), 7.25~7.17 (m, 2H, ArH), 6.29 (s, 1H, =CH2), 5.58 (s, 1H, =CH2), 3.48 (d, J=18.6 Hz, 1H, CH2), 3.21 (d, J=17.4 Hz, 1H, CH2), 2.29 (s, 3H, CH3); 13C NMR (150 MHz, CDCl3) δ: 165.9, 165.8, 138.4, 134.2, 133.0, 132.9, 131.3, 129.1, 128.7, 128.3, 128.2, 127.0, 125.8 (q, JC-F=285.8 Hz), 124.3, 119.8, 68.7 (q, JC-F=28.5 Hz), 37.0, 21.2; 19F NMR (564MHz, CDCl3) δ: -71.9; HRMS (ESI) calcd for C20H18F3N2O2 [M+H]+ 375.1315, found 375.1311.
N-(2-甲基苯甲酰胺基)-α-亚甲基-γ-苯基-γ-三氟甲基-γ-丁内酰胺(6e):白色固体; 38.2 mg, 产率51%. m.p. 53~55 ℃; 1H NMR (400 MHz, CDCl3) δ: 7.64 (d, J=7.2 Hz, 2H, NH), 7.44~7.36 (m, 3H, ArH), 7.30~7.20 (m, 3H, ArH), 7.15~7.08 (m, 2H, ArH), 6.28 (s, 1H, =CH2), 5.57 (s, 1H, =CH2), 3.48 (d, J=18.0 Hz, 1H, CH2), 3.22 (d, J=17.6 Hz, 1H, CH2), 2.24 (s, 3H, CH3); 13C NMR (150 MHz, CDCl3) δ: 167.7, 165.3, 137.1, 134.2, 132.9, 131.0, 130.7, 129.2, 128.8, 127.0, 125.8 (q, JC-F=285.5 Hz), 125.6, 119.9, 116.0, 68.5 (q, JC-F=27.6 Hz), 37.0, 19.2; 19F NMR (376 MHz, CDCl3)δ: -72.3; HRMS (ESI) calcd for C20H18F3N2O2[M+H]+ 375.1315, found 375.1309.
N-(4-氯苯甲酰胺基)-α-亚甲基-γ-苯基-γ-三氟甲基-γ-丁内酰胺(6f):白色固体; 61.5 mg, 产率78%. m.p. 66~67 ℃; 1H NMR (600 MHz, CDCl3) δ: 9.08 (s, 1H, NH), 7.60 (d, J=6.6 Hz, 2H, ArH), 7.47 (d, J=8.4 Hz, 2H, ArH), 7.35~7.30 (m, 3H, ArH), 7.16 (d, J=8.4 Hz, 2H, ArH), 6.30 (s, 1H, =CH2), 5.63 (s, 1H, =CH2), 3.46 (d, J=18.0 Hz, 1H, CH2), 3.25 (d, J=18.0 Hz, 1H, CH2); 13C NMR (150 MHz, CDCl3) δ: 166.7, 164.2, 138.4, 133.6, 133.0, 129.2, 129.0, 128.8, 128.5, 128.4, 127.2, 125.7 (q, JC-F=286.1 Hz), 120.1, 68.9 (q, JC-F=27.2 Hz), 37.0; 19F NMR (376 MHz, CDCl3) δ: -72.7; HRMS (ESI) calcd for C19H16ClF3N2O2[M+H]+ 395.0769, found 395.0766.
N-(2-呋喃甲酰胺基)-α-亚甲基-γ-苯基-γ-三氟甲基-γ-丁内酰胺(6g):白色固体; 56.2 mg, 产率80%. m.p. 74~76 ℃; 1H NMR (600 MHz, CDCl3) δ: 8.11 (s, 1H, NH), 7.62 (d, J=7.8 Hz, 2H, ArH), 7.40 (t, J=7.2 Hz, 2H, ArH), 7.37~7.34 (m, 2H, ArH, C4H3O, ), 7.10 (d, J=3.6 Hz, 1H, C4H3O), 6.41 (dd, J=3.6, 1.8 Hz, 1H, C4H3O), 6.31 (s, 1H, =CH2), 5.59 (s, 1H, =CH2), 3.49 (d, J=18.0 Hz, 1H, CH2), 3.19 (d, J=18.0 Hz, 1H, CH2); 13C NMR (150 MHz, CDCl3) δ: 165.6, 156.2, 145.4, 144.8, 134.2, 132.8, 129.1, 128.8, 126.9, 125.7 (q, JC-F=285.5 Hz), 119.9, 116.6, 112.1, 68.6 (q, JC-F=28.5 Hz), 37.1; 19F NMR (376 MHz, CDCl3) δ: -72.1; HRMS (ESI) calcd for C17H14F3N2O3 [M+H]+ 351.0951, found 351.0948.
N-苯甲酰胺基-α-亚甲基-γ-(4-甲氧基苯基)-γ-三氟甲基-γ-丁内酰胺(6h):白色固体; 67.1 mg, 产率86%. m.p. 124~126 ℃; 1H NMR (600 MHz, CDCl3) δ: 8.89 (br, NH, 1H), 7.53 (d, J=7.8 Hz, 4H, ArH), 7.35 (t, J=7.2 Hz, 1H, ArH), 7.20 (t, J=7.2 Hz, 2H, ArH), 6.83 (d, J=8.4 Hz, 2H, ArH), 6.25 (s, 1H, =CH2), 5.57 (s, 1H, =CH2), 3.72 (OCH3, s, 3H), 3.42 (d, J=18.0 Hz, 1H, CH2), 3.21 (d, J=17.4 Hz, 1H, CH2); 13C NMR (150 MHz, CDCl3) δ: 166.4, 165.4, 159.7, 133.3, 131.9, 130.9, 128.7, 128.2, 127.5, 125.8 (q, JC-F=286.5 Hz), 125.4, 124.8, 119.5, 113.8, 68.5 (q, JC-F=27.0 Hz), 55.1, 36.9; 19F NMR (376 MHz, CDCl3) δ: -72.9; HRMS (ESI) calcd for C20H18F3N2O3 [M+H]+ 391.1264, found 391.1261.
N-苯甲酰胺基-α-亚甲基-γ-(4-甲基苯基)-γ-三氟甲基-γ-丁内酰胺(6i):白色固体; 61.5 mg, 产率82%. m.p. 98~100 ℃; 1H NMR (600 MHz, CDCl3) δ: 8.12 (br, 1H, NH), 7.59 (d, J=7.2 Hz, 2H, ArH), 7.49 (d, J=7.8 Hz, 2H, ArH), 7.43 (s, 1H, ArH), 7.33~7.29 (m, 2H, ArH), 7.17 (d, J=7.2 Hz, 2H, ArH), 6.29 (s, 1H, =CH2), 5.58 (s, 1H, =CH2), 3.46 (d, J=18.0 Hz, 1H, CH2), 3.20 (d, J=17.4 Hz, 1H, CH2), 2.31 (s, 3H, CH3); 13C NMR (150 MHz, CDCl3) δ: 166.5, 165.3, 139.1, 133.1, 132.2, 131.3, 131.1, 129.4, 128.5, 127.5, 126.9, 125.8 (q, JC-F=285.0 Hz), 119.7, 68.6 (q, JC-F=28.5 Hz), 37.0, 21.0; 19F NMR (564MHz, CDCl3) δ: -72.2; HRMS (ESI) calcd for C20H18F3N2O2 [M+H]+ 375.1315, found 375.1317.
N-苯甲酰胺基-α-亚甲基-γ-(4-氯苯基)-γ-三氟甲基-γ-丁内酰胺(6j):白色固体; 61.6 mg, 产率78%. m.p. 74~76 ℃; 1H NMR (600 MHz, CDCl3) δ: 8.68 (s, 1H, NH), 7.58 (d, J=8.4 Hz, 2H, ArH), 7.55 (d, J=7.8 Hz, 2H, ArH), 7.40 (t, J=7.2 Hz, 1H, ArH, ), 7.31 (d, J=9.0 Hz, 2H, ArH), 7.25 (ArH, t, J=6.6 Hz, 2H), 6.29 (s, 1H, =CH2), 5.61 (s, 1H, =CH2), 3.45 (d, J=18.0 Hz, 1H, CH2), 3.18 (d, J=17.4 Hz, 1H, CH2); 13C NMR (150 MHz, CDCl3) δ: 166.4, 165.4, 142.5, 134.0, 133.1, 128.9, 128.8, 128.5, 128.0, 127.5, 127.1, 125.7 (q, JC-F=285.0 Hz), 119.6, 68.8 (q, JC-F=28.5 Hz), 36.9;19F NMR (376 MHz, CDCl3) δ: -72.5; HRMS (ESI) calcd for C19H15ClF3N2O2[M+H]+ 395.0769, found 395.0762.
N-苯甲酰胺基-α-亚甲基-γ-(3-氯苯基)-γ-三氟甲基-γ-丁内酰胺(6k):白色固体; 55.3 mg, 产率70%. m.p. 62~64 ℃; 1H NMR (600 MHz, CDCl3) δ: 8.82 (br, 1H, NH), 7.64 (s, 1H, ArH), 7.56~7.54 (m, 3H, ArH), 7.39 (t, J=7.6 Hz, 1H, ArH), 7.29~7.20 (m, 4H, ArH), 6.30 (s, 1H, =CH2), 5.61 (s, 1H, =CH2), 3.45 (d, J=18.0 Hz, 1H, CH2), 3.19 (d, J=18.0 Hz, 1H, CH2); 13C NMR (150 MHz, CDCl3) δ: 166.3, 165.5, 135.9, 134.4, 132.5, 132.1, 130.7, 129.9, 129.4, 128.3, 127.5, 127.4, 125.6, 125.4 (q, JC-F=285.0 Hz), 120.2, 68.5 (q, JC-F=28.5 Hz), 36.7; 19F NMR (376 MHz, CDCl3) δ: -72.5; HRMS (ESI) calcd for C19H15ClF3N2O2[M+H]+ 395.0769, found 395.0764.
N-苯甲酰胺基-α-亚甲基-γ-(3-溴苯基)-γ-三氟甲基-γ-丁内酰胺(6l):白色固体; 63.1 mg, 产率72%. m.p. 88~90 ℃; 1H NMR (400 MHz, CDCl3) δ: 8.58 (s, 1H, NH), 7.78 (s, 1H, ArH), 7.61~7.55 (m, 3H, ArH), 7.46~7.38 (m, 2H, ArH), 7.27~7.20 (m, 3H, ArH), 6.30 (s, 1H, =CH2), 5.61 (s, 1H, =CH2), 3.45 (d, J=18.0 Hz, 1H, CH2), 3.18 (d, J=18.0 Hz, 1H, CH2); 13C NMR (150 MHz, CDCl3) δ: 166.1, 165.6, 136.2, 132.5, 132.3, 132.2, 130.9, 130.3, 130.2, 128.4, 127.5, 126.0, 125.5 (q, JC-F=286.5 Hz), 122.5, 120.3, 68.4 (q, JC-F=27.0 Hz), 36.8; 19F NMR (376 MHz, CDCl3) δ: -72.5; HRMS (ESI) cacld for C19H15BrF3N2O2 [M+H]+ 438.0264, found 439.0258.
辅助材料(Supporting Information) 合成产物的核磁共振氢谱、碳谱和氟谱以及高分辨质谱.这些材料可以免费从本刊网站(http://sioc-journal.cn/)上下载.
-
-
[1]
(a) Basavaiah, D.; Reddy, G. C.; Bharadwaj, K. C. Eur. J. Org. Chem. 2014, 1157.
(b) Janecka, A.; Wyrebska, A.; Gach, K.; Fichna, J.; Janecki, T. Drug Discovery Today 2012, 17, 561.
(c) Pan, F.; Chen, J.-M.; Qin, T.-Y.; Zhang, S. X.-A.; Liao, W.-W. Eur. J. Org. Chem. 2012, 5324.
(d) Millemaggi, A.; Taylor, R. J. K. Eur. J. Org. Chem. 2010, 4527. -
[2]
(a) Companyo, X.; Geant, P.-Y.; Mazzanti, A.; Moyano, A.; Rios, R. Tetrahedron 2014, 70, 75.
(b) Companyo, X.; Mazzanti, A.; Moyano, A.; Janecka, A.; Rios, R. Chem. Commun. 2013, 49, 1184.
(c) Krawczyk, H.; Albrecht, Ł.; Wojciechowski, J.; Wolf, W. M.; Krajewska, U.; Różalski, M. Tetrahedron 2008, 64, 6307.
(d) Janecki, T.; Błaszczyk, E.; Studzian, K.; Janecka, A.; Krajewska, U.; Różalski, M. J. Med. Chem. 2005, 48, 3516. -
[3]
(a) Albrecht, A. ; Albrecht, Ł. ; Janecki, T. Eur. J. Org. Chem. 2011, 2747.
(b) Jiang, H. Chin. J. Org. Chem. 1996, 16, 415(in Chinese).
(江焕峰, 有机化学, 1996, 16, 415. ) -
[4]
(a) Reddy, L. R.; Fournier, J.-F.; Subba Reddy, B. V.; Corey, E. J. J. Am. Chem. Soc. 2005, 127, 8974.
(b) Krishna, P. R.; Kannan, V.; Sharma, G. V. M. J. Org. Chem. 2004, 69, 6467. -
[5]
(a) Li, X.; Su, J.; Liu, J.; Zhu, Y.; Dong, Z.; Qiu, S.; Wang, J.; Lin, L.; Shen, Z.; Yan, W.; Wang, K.; Wang, R. Org. Lett. 2016, 18, 956.
(b) Xu, J.; Chen, J.; Yang, Q.; Ding, L.; Liu, X.; Xu, D.; Zhao, B. Adv. Synth. Catal. 2014, 356, 3219.
(c) Just, M. J.; Tekkam, S.; Alam, M. A.; Jonnalagadda, S. C.; Johnson, J. L.; Mereddy, V. R. Tetrahedron Lett. 2011, 52, 5349.
(d) Lee, K.-Y.; Lee, Y.-J.; Kim, J.-N. Bull. Korean Chem. Soc. 2007, 28, 143. -
[6]
(a) Krawczyk, H.; Albrecht, Ł.; Wojciechowski, J.; Wolf, W. M.; Krajewska, U.; Roź alski, M. Tetrahedron 2008, 64, 6307.
(b) Albrecht, A.; Koszuk, J. F.; Modranka, J.; Różalski, M.; Krajewska, U.; Janecka, A.; Janecki, T. Bioorg. Med. Chem. 2008, 16, 4872.
(c) Bower, J. F.; Williams, A. J.; Woodward, H. L.; Szeto, P.; Lawrence, R. M.; Gallagher, T. Org. Biomol. Chem. 2007, 5, 2636. -
[7]
(a) Choudhury, P. K.; Foubelo, F.; Yus, M. J. Org. Chem. 1999, 64, 3376.
(b) Nyzam, V.; Belaud, C.; Zammattio, F.; Villieras, J. Tetrahedron:Asymmetry 1996, 7, 1835.
(c) Alami, N. E.; Belaud, C.; Villieras, J. Tetrahedron Lett. 1987, 28, 59. -
[8]
(a) Tojino, M.; Otsuka, N.; Fukuyama, T.; Matsubara, H.; Ryu, I. J. Am. Chem. Soc. 2006, 128, 7712.
(b) Tojino, M.; Uenoyama, Y.; Fukuyama, T.; Ryu, I. Chem. Commun. 2004, 2482.
(c) Ryu, I.; Miyazato, H.; Kuriyama, H.; Matsu, K.; Tojino, M.; Fukuyama, T.; Minakata, S.; Komatsu, M. J. Am. Chem. Soc. 2003, 125, 5632. -
[9]
(a) Shen, A.; Liu, M.; Jia, Z.-S.; Xu, M.-H.; Lin, G.-Q. Org. Lett. 2010, 12, 5154.
(b) Lee, A. S.-Y.; Chang, Y.-T. Tetrahedron Lett. 2010, 51, 3800. -
[10]
Choudhury, P. K.; Foubelo, F.; Yus, M. J. Org. Chem. 1999, 64, 3376. doi: 10.1021/jo982311m
-
[11]
Xu, Y.; Huang, D.; Wang, K.-H.; Ma, J.; Su, Y.; Fu, Y.; Hu, Y. J. Org. Chem. 2015, 80, 12224. doi: 10.1021/acs.joc.5b02154
-
[12]
(a) Elford, T. G.; Ulaczyk-Lesanko, A.; De Pascale, G.; Wright, G. D.; Hall, D. G. J. Comb. Chem. 2009, 11, 155.
(b) Elford, T. G.; Hall, D. G. Tetrahedron Lett. 2008, 49, 6995.
(c) Chataigner, I.; Zammattio, F.; Lebreton, J.; Villiéras, J. Tetrahedron 2008, 64, 2441. -
[13]
(a) Yang, X.; Wu, T.; Phipps, R. J.; Toste, F. D. Chem. Rev. 2015, 115, 826.
(b) Nie, J.; Guo, H.-C.; Cahard, D.; Ma, J.-A. Chem. Rev. 2011, 111, 455.
(c) Purser, S.; Moore, P. R.; Swallow, S.; Gouverneur, V. Chem. Soc. Rev. 2008, 37, 320. -
[14]
For typical reviews, see:(a) Meyer, F. Chem. Commun. 2016, 52, 3077.
(b) Alonso, C.; Martinez de Marigorta, E.; Rubiales, G.; Palacios, F. Chem. Rev. 2015, 115, 1847.
(c) Ni, C.; Hu, M.; Hu, J. Chem. Rev. 2015, 115, 765.
(d) Liu, X.; Xu, C.; Wang, M.; Liu, Q. Chem. Rev. 2015, 115, 683.
(e) Charpentier, J.; Fruth, N.; Togni, A. Chem. Rev. 2015, 115, 650.
(f) Liang, T.; Neumann, C. N.; Ritter, T. Angew. Chem., Int. Ed. 2013, 52, 8214.
(g) Qing, F.-L. Chin. J. Org. Chem. 2012, 32, 815(in Chinese).
(卿凤翎, 有机化学, 2012, 32, 815.) -
[15]
For recent articles, see:(a) Rong, J.; Ni, C.; Wang, Y.; Kuang, C.; Gu, Y.; Hu, J. Acta Chim. Sinica 2017, 75, 105(in Chinese).
(荣健, 倪传法, 王云泽, 匡翠文顾玉诚, 胡金波, 化学学报, 2017, 75, 105. )
(b) Gou, B.; Yang, C.; Zhang, L.; Xia, W. Acta Chim. Sinica 2017, 75, 66(in Chinese).
(苟宝权, 杨超, 张磊, 夏吾炯, 化学学报, 2017, 75, 66. )
(c) Zheng, G.; Liu, H.; Wang, M. Chin. J. Chem. 2016, 34, 519.
(d) Li, T.; Yu, P.; Lin, J. -S.; Zhi, Y.; Liu, X. -Y. Chin. J. Chem. 2016, 34, 490.
(e) Saidalimu, I.; Suzuki, S.; Tokunaga, E.; Shibata, N. Chin. J. Chem. 2016, 34, 485.
(f) Ge, G.; Huang, X.; Ding, C.; Li, H.; Wan, S.; Hou, X. Chin. J. Chem. 2014, 32, 727.
(g) Barata-Vallejo, S.; Lantaño, B.; Postigo, A. Chem. Eur. J. 2014, 20, 16806. -
[16]
(a) Zhang, W. ; Su, Y. ; Wang, K. -H. ; Wu, L. ; Chang, B. ; Shi, Y. ; Huang, D. ; Hu, Y. Org. Lett. 2017, 19, 376.
(b) Zhang, W. ; Su, Y. ; Chong, S. ; Wu, L. ; Cao, G. ; Huang, D. ; Wang, K. -H. ; Hu, Y. Org. Biomol. Chem. 2016, 14, 11162.
(c) Du, G. ; Huang, D. ; Wang, K. -H. ; Chen, X. ; Xu, Y. ; Ma, J. ; Su, Y. ; Hu, Y. Org. Biomol. Chem. 2016, 14, 1492.
(d) Ji, S. ; Alkhalil, A. E. ; Su, Y. ; Xia, X. ; Chong, S. ; Wang, K. -H. ; Huang, D. ; Fu, Y. ; Hu, Y. Synlett 2015, 1725.
(e) Wang, K. -H. ; Wang, Y. ; Yin, X. ; Peng, X. ; Huang, D. ; Su, Y. ; Hu, Y. Chin. J. Org. Chem. 2017, 37, 1764(in Chinese).
(王克虎, 王雅琳, 殷雪娇, 彭先沙, 黄丹凤, 苏瀛鹏, 胡雨来, 有机化学, 2017, 37, 1764. ) -
[17]
李军, 杨天宇, 张怀远, 黄丹凤, 王克虎, 苏瀛鹏, 胡雨来, 有机化学, 2017, 37, 925. http://sioc-journal.cn/Jwk_yjhx/CN/abstract/abstract345872.shtmlLi, J.; Yang, T.; Zhang, H.; Huang, D.; Wang, K.-H.; Su, Y.; Hu, Y. Chin. J. Org. Chem. 2017, 37, 925(in Chinese). http://sioc-journal.cn/Jwk_yjhx/CN/abstract/abstract345872.shtml
-
[18]
Xu, Y.; Huang, D.; Wang, K.-H.; Ma, J.; Su, Y.; Fu, Y.; Hu, Y. J. Org. Chem. 2015, 80, 12224. doi: 10.1021/acs.joc.5b02154
-
[19]
(a) Shen, Z.-L.; Wang, S.-Y.; Chok, Y.-K.; Xu, Y.-K.; Loh, T.-P. Chem. Rev. 2013, 113, 271.
(b) Kornblum, N.; Chen, S. I.; Kelly, W. J. J. Org. Chem. 1988, 53, 1831. -
[20]
陈文杰, 廖道华, 化学世界, 2006, 285. doi: 10.3969/j.issn.0367-6358.2006.05.010Chen, W.; Liao, D. Chem. World 2006, 285(in Chinese). doi: 10.3969/j.issn.0367-6358.2006.05.010
-
[1]
-
表 1 酰肼的适用范围a
Table 1. Substrate scope of acylhydrazines
Entry R1 Product Isolated yield/% 1 C6H5 4a 81 2 o-MeC6H4 4b Trace 3 m-MeC6H4 4c 51 4 p-MeC6H4 4d 84 5 p-MeOC6H4 4e 89 6 p-FC6H4 4f 71 7 p-ClC6H4 4g 73 8 p-CF3C6H4 4h 86 9 m-BrC6H4 4i 75 10 2-Furyl 4j 81 11 2-Naphthyl 4k 72 12 Me — 0 13 n-C17H35 — 0 aA mixture of 1 (0.3 mmol), acylhydrazine (0.2 mmol) in EtOH (4.0 mL) was stirred at reflux for 3 h, then 3 (0.5 mmol) and in powder (0.3 mmol) were added and stirred at reflux for another 21 h. 表 2 合成化合物6a反应条件优化a
Table 2. Optimization of reaction condition for the synthesis of compound 6a
Entry Molar ratio of 5a/2a/3/In Catalyst/mol% Isolated yield/% 1 1/1.2/2.5/1.5 PTSA (20) 47 2 1/1.2/2.5/1.5 PTSA (20) Ni(ClO)4·6H2O (10) 52 3 1/1.2/3/1.5 PTSA (20) 54 4 1/1.2/3/2 PTSA (20) 56 5 1/1.2/3.5/2 PTSA (20) 72 6 1/1.2/3.5/2.5 PTSA (20) 80 a A mixture of 5a (0.2 mmol), 2a (0.24 mmol), catalyst (20 mol%, 0.04 mmol) in EtOH (3.0 mL) was stirred at reflux for 5 h, then 3(0.5~0.7 mmol). In powder (0.3~0.5 mmol) were added and stirred at reflux for another 19 h. 表 3 三氟甲基酮和酰肼的适用范围a
Table 3. Substrate scope of trifluoromethylketones and acylhydrazines
Entry R1 R2 Product Isolated yield/% 1 Ph Ph 6a 80 2 p-MeOC6H4 Ph 6b 83 3 p-MeC6H4 Ph 6c 82 4 m-MeC6H4 Ph 6d 74 5 o-MeC6H4 Ph 6e 51 6 p-ClC6H4 Ph 6f 78 7 p-CF3C6H4 Ph — 0 8 2-Furyl Ph 6g 80 9 Ph p-MeOC6H4 6h 86 10 Ph p-MeC6H4 6i 82 11 Ph p-ClC6H4 6j 78 12 Ph m-ClC6H4 6k 70 13 Ph o-ClC6H4 — Trace 14 Ph m-BrC6H4 6l 72 15 Ph p-CF3C6H4 — 0 16 Me Ph — 0 a A mixture of 5 (0.2 mmol), 2(0.24 mmol), PTSA (20 mol%, 0.04 mmol) in EtOH (3.0 mL) was stirred at reflux for 5 h, then 3(0.7 mmol). In powder (0.5 mmol) were added and stirred at reflux for another 19 h. -

计量
- PDF下载量: 1
- 文章访问数: 2596
- HTML全文浏览量: 121